Brokerages Set Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target at $34.00

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) has received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $34.00.

Several research analysts have commented on ARQT shares. Needham & Company LLC reaffirmed a “buy” rating and set a $36.00 target price on shares of Arcutis Biotherapeutics in a report on Thursday. Guggenheim lifted their target price on Arcutis Biotherapeutics from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Wall Street Zen downgraded Arcutis Biotherapeutics from a “buy” rating to a “hold” rating in a report on Saturday. TD Cowen lifted their target price on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, HC Wainwright lifted their target price on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, February 26th.

Arcutis Biotherapeutics News Roundup

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $34 price target on Arcutis Biotherapeutics while raising near-term EPS estimates for 2026 quarters, reinforcing the view that earnings could improve as ZORYVE sales scale. Article Title
• Positive Sentiment: Needham also reiterated its Buy rating with a $36 target, helping sentiment by signaling that analysts still see meaningful upside from current levels.
• Positive Sentiment: The company reported a $105.4 million quarterly revenue beat and highlighted strong ZORYVE momentum, including commercial growth and pipeline progress, which remains a key driver for investor enthusiasm. Article Title
• Neutral Sentiment: Arcutis announced inducement grants to 40 new hires, a routine equity compensation move that signals continued hiring but is not likely to materially change the stock’s near-term outlook. Article Title
• Neutral Sentiment: HC Wainwright’s mix of higher and lower out-year estimates suggests analysts remain constructive overall, but are still fine-tuning the longer-term earnings model. Article Title
• Negative Sentiment: Q1 EPS missed expectations, showing Arcutis is still spending heavily as it grows; that profitability gap could limit upside if investors focus on margins rather than sales growth. Article Title
• Negative Sentiment: Several insiders sold shares under pre-arranged 10b5-1 plans, which is routine, but clustered selling can still weigh on sentiment in the short term. Article Title

Arcutis Biotherapeutics Price Performance

Shares of ARQT opened at $21.17 on Wednesday. The company has a market capitalization of $2.65 billion, a PE ratio of -705.43 and a beta of 1.58. Arcutis Biotherapeutics has a 12 month low of $12.72 and a 12 month high of $31.77. The stock’s 50-day moving average price is $23.65 and its two-hundred day moving average price is $25.77. The company has a current ratio of 2.68, a quick ratio of 2.46 and a debt-to-equity ratio of 0.54.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its earnings results on Wednesday, May 6th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.07). The company had revenue of $105.40 million for the quarter, compared to analyst estimates of $103.68 million. Arcutis Biotherapeutics had a negative return on equity of 1.41% and a negative net margin of 0.57%. On average, analysts anticipate that Arcutis Biotherapeutics will post 0.15 EPS for the current year.

Insider Activity

In related news, insider Masaru Matsuda sold 8,733 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $25.30, for a total transaction of $220,944.90. Following the transaction, the insider directly owned 136,932 shares of the company’s stock, valued at approximately $3,464,379.60. This represents a 6.00% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Todd Watanabe sold 37,349 shares of the company’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $25.18, for a total value of $940,447.82. Following the transaction, the insider directly owned 785,957 shares in the company, valued at approximately $19,790,397.26. This trade represents a 4.54% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 92,831 shares of company stock worth $2,295,499. 9.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC increased its holdings in Arcutis Biotherapeutics by 21.4% during the 1st quarter. AQR Capital Management LLC now owns 248,196 shares of the company’s stock worth $3,882,000 after purchasing an additional 43,716 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Arcutis Biotherapeutics by 3.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 71,417 shares of the company’s stock worth $1,118,000 after purchasing an additional 2,063 shares in the last quarter. Creative Planning increased its holdings in Arcutis Biotherapeutics by 8.2% during the 2nd quarter. Creative Planning now owns 19,575 shares of the company’s stock worth $274,000 after purchasing an additional 1,477 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in Arcutis Biotherapeutics by 1.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 548,789 shares of the company’s stock worth $7,694,000 after purchasing an additional 5,407 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Arcutis Biotherapeutics by 4,562.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 11,190 shares of the company’s stock worth $157,000 after purchasing an additional 10,950 shares in the last quarter.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.